NL-OMON38087已完成不适用
Caphosol as a therapeutic option in patients with breast- or colorectal cancer at risk for chemotherapy-induced oral mucositis - TOPCOM
Maxima Medisch Centrum0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Patients 18 years or older
- •* Patients first diagnosed with breast cancer receiving FE100C x6, FE100C x3 and docetaxel x3, TAC x6, FAC x6, AC x4 followed with Docetaxel x4, AC x4 followed with Docetaxel/Trastuzumab x4. Patients diagnosed with first colorectal cancer receiving FOLFOX-IV x9 (+/- bevacizumab), XelOx x8 (+/- bevacizumab)
- •* Patients with clinically assessed >grade 2 oral mucositis in any of the first three cycles of chemotherapy and that receive at least two subsequent chemotherapy cycles of the same therapeutic agent
- •* Willingness not to use marketed oral mucositis drugs, rinses or artificial saliva (Gelclair, Mugard, Evomucy, Biotene, Oral Balance, Magic Mouthwash) for 2 cycles when on standard oral care
- •* Written informed consent
排除标准
- •*Receiving palifermin
- •*Receiving low level laser therapy
- •*Dose adjustment in chemotherapy dosages up till the chemotherapy cycle following the chemotherapy cycle in which oral mucositis > grade 2 is assessed.
研究者
相似试验
尚未招募
3 期
Caphosol, a therapeutic option in cancer therapy induced mucositis in children.Stomatitismucositisdenture sore mouth.NL-OMON35477niversitair Medisch Centrum Groningen30
已完成
不适用
Onderzoek naar de werkzaamheid van Caphosol tegen mucositis bij kinderen met kanker.Hospitalised children with cancer therapy induced mucositisNL-OMON24436niversitair Centrum van Groningen, Utrecht, VU en Leiden30
进行中（未招募）
不适用
THE USE OF CASPOFUNGIN(CANCIDAS) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCES AND CONCOMITANT CANDIDEMIACANDIDEMIA IN HEMATOLOGICAL MALIGNANCIESMedDRA version: 6.1Level: PTClassification code 10042938EUCTR2004-004266-32-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
已完成
2 期
Plasmapheresis in the treatment of patients with COVID-19coronavirus disease (covid-19).Coronavirus as the cause of diseases classified elsewhereB97.2IRCT20180316039112N3Iran University of Medical Sciences100
进行中（未招募）
2 期
se of plasma of cured person to treat patient with severe covid-19Coronavirus infection, transfusion, C23, A00-B99, Coronavirus OC43, Human.A00-B99RBR-7f4mt9fHemocentro de Ribeirão Preto